Secukinumab is a fully human immunoglobulin G1-kappa моноклональный антитело that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing
Secukinumab is a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.